Search Results

According to the Skin Cancer Foundation, 90% of skin aging is caused by the sun,1 and even with proper SPF usage, harmful UV rays can still penetrate the skin.

HCW Biologics Inc. will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.

Nura Pain Clinics, the Twin Cities’ foremost multidisciplinary pain management clinic, announced today that the first patient in Minnesota has been implanted with the new Medtronic SynchroMed™ III implantable drug pump for the treatment of chronic pain.

Inspired Spine has announced the establishment of two new Centers of Excellence focused on providing complex spine care, including fusion surgeries, to patients with high Body Mass Index in rural areas of Minnesota and Kansas, a groundbreaking turn in modern spine health management.

Immusoft today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for compositions of matter and methods to make and use genome edited primary B cells.

Justin Zenanko, CEO of SynerFuse™, is proud to announce that Michael Park, M.D., associate professor of neurosurgery at the University of Minnesota, SynerFuse IDE Proof of Concept study PI, presented data from the Proof of Concept study’s first eight patients at the 10th annual Minnesota Neuromodulation Symposium, April 21, 2023.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Citius Pharmaceuticals, Inc. today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas.